Legend Biotech (LEGN) FCF Margin (2019 - 2025)
Legend Biotech (LEGN) reported FCF Margin of 3.98% for Q4 2025, up 5389.0% on a YoY basis from 0.07% in Q4 2024, and down 132.09% quarter-over-quarter from 12.41% in Q3 2025.
Legend Biotech (LEGN) FCF Margin (2019 - 2025) Analysis & Trends
Legend Biotech has reported FCF Margin for 7 years, with the latest figure at 3.98% in Q4 2025.
- For the quarter ending Q4 2025, FCF Margin rose 5389.0% year-over-year to 3.98%; the trailing twelve-month figure through Dec 2025 stood at 8.16% (up 1705.0% YoY), and the FY2025 full-year result was 9.74%, up 1547.0% from the prior year.
- FCF Margin for Q4 2025 stood at 3.98%, down from 12.41% in the prior quarter.
- The five-year high for FCF Margin was 23.15% in Q1 2024, with the low at 400.74% in Q4 2021.
- Historically, FCF Margin has averaged 103.87% across 5 years, with a median of 57.82% in 2023.
- Annual changes were most pronounced in 2023 — FCF Margin slumped 23834 bps — and 2024, when it surged 39452 bps.
- Legend Biotech's FCF Margin stood at 400.74% in 2021, then soared by 74 bps to 104.28% in 2022, then soared by 100 bps to 0.17% in 2023, then sank by 34880 bps to 57.87% in 2024, then soared by 93 bps to 3.98% in 2025.
- The last three FCF Margin figures came in at 3.98% (Q4 2025), 12.41% (Q3 2025), and 1.5% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -3.98% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 43.35% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Regeneron Pharmaceuticals | 63.43 Bn | 54.67 Bn | 3.31 Bn | 23.53% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -3.98% |
| Sep 30, 2025 | 12.41% |
| Jun 30, 2025 | -1.50% |
| Mar 31, 2025 | -52.17% |
| Dec 31, 2024 | -57.87% |
| Sep 30, 2024 | -46.04% |
| Jun 30, 2024 | 0.95% |
| Mar 31, 2024 | 23.15% |
| Dec 31, 2023 | -0.17% |
| Sep 30, 2023 | -57.77% |
| Jun 30, 2023 | -124.75% |
| Mar 31, 2023 | -371.37% |
| Dec 31, 2022 | -104.28% |
| Sep 30, 2022 | -254.14% |
| Jun 30, 2022 | -8.87% |
| Mar 31, 2022 | -133.03% |
| Dec 31, 2021 | -400.74% |
| Sep 30, 2021 | -196.14% |
| Jun 30, 2021 | -217.91% |
| Mar 31, 2021 | -83.17% |